Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
Resolv ER may remedy leading causes of blindness in adults
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Subscribe To Our Newsletter & Stay Updated
